1-(1-oxy-pyridin-4-yl)ethanol | 39585-72-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(1-oxy-pyridin-4-yl)ethanol
• 英文别名: 4-(1-Hydroxyethyl)-pyridin-N-oxid；4-(α-Hydroxyethyl)-pyridin-1-oxid；1-(1-Oxidopyridin-1-ium-4-yl)ethanol
• CAS: 39585-72-3
• 化学式: C₇H₉NO₂
• 分子量: 139.154
• InChiKey: JFVOZIKGNOVQKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  45.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1-oxy-pyridin-4-yl)ethanol 、 3-苯基丙酸乙烯酯 在 4 A molecular sieve 、 Lipase from Burkholderia cepacia 作用下， 以 1,4-二氧六环 为溶剂， 反应 48.0h， 生成 (S)-dihydrocinnamic acid 1-(1-oxy-pyridin-4-yl)ethyl ester 、 (R)-dihydrocinnamic acid 1-(1-oxy-pyridin-4-yl)ethyl ester 、 (1S)-1-(1-氧代-4-吡啶基)乙醇 、 (R)-1-(1-oxy-pyridin-4-yl)ethanol
  参考文献：
  名称：

  How Substrate Solvation Contributes to the Enantioselectivity of Subtilisin toward Secondary Alcohols

  摘要：

  The current rule to predict the enantiopreference of subtilisin toward secondary alcohols is based on the size of the substituents at the stereocenter and implies that the active site contains two differently sized pockets for these substituents. Several experiments are inconsistent with the current rule. First, the X-ray structures of subtilisin show there is only one pocket (the S1' pocket) approximately the size of a phenyl group to bind secondary alcohols. Second, the rule often predicts the incorrect enantiomer for reactions in water. To resolve these contradictions, we refine the current rule to show that subtilisin binds only one substituent of a secondary alcohol and leaves the other in solvent. To test this refined empirical rule, we show that the enantioselectivity of a series of secondary alcohols in water varied linearly with the difference in hydrophobicity (log P/P0) of the substituents. This hydrophobicity difference accounts for the solvation of one substituent in water.

  DOI：

  10.1021/ja0528937
• 作为产物：
  描述：

  1-(4-吡啶基)乙醇 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 以95%的产率得到1-(1-oxy-pyridin-4-yl)ethanol
  参考文献：
  名称：

  How Substrate Solvation Contributes to the Enantioselectivity of Subtilisin toward Secondary Alcohols

  摘要：

  The current rule to predict the enantiopreference of subtilisin toward secondary alcohols is based on the size of the substituents at the stereocenter and implies that the active site contains two differently sized pockets for these substituents. Several experiments are inconsistent with the current rule. First, the X-ray structures of subtilisin show there is only one pocket (the S1' pocket) approximately the size of a phenyl group to bind secondary alcohols. Second, the rule often predicts the incorrect enantiomer for reactions in water. To resolve these contradictions, we refine the current rule to show that subtilisin binds only one substituent of a secondary alcohol and leaves the other in solvent. To test this refined empirical rule, we show that the enantioselectivity of a series of secondary alcohols in water varied linearly with the difference in hydrophobicity (log P/P0) of the substituents. This hydrophobicity difference accounts for the solvation of one substituent in water.

  DOI：

  10.1021/ja0528937

文献信息

• [EN] 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS<br/>[FR] COMPOSES INDOLE 2,3-SUBSTITUES UTILISES COMME INHIBITEURS DE COX-2
  申请人：PFIZER PHARMACEUTICALS INC.

  公开号：WO1999035130A1

  公开（公告）日：1999-07-15

  (EN) This invention provides a compound of formula (I) or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, -NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C3-7 cycloalkyl and (e) an optionally substituted benzofuzed heterocycle; R1 is hydrogen, C1-4 alkyl or halo; R2 and R3 are independently hydrogen, OH, C1-4 alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 alkyl)amino and CN; and n is 0, 1, 2, 3 and 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.(FR) Cette invention porte sur un composé de la formule (I) ou sur les sels pharmaceutiquement acceptables de celui-ci, formule dans laquelle Z représente OH, alcoxy C1-6, -NR2R3 ou un hétérocycle; Q est sélectionné parmi: (a) un phényle éventuellement substitué, (b) un groupe aromatique monocyclique à 6 éléments éventuellement substitué contenant un, deux, trois ou quatre atomes d'azote, (c) un groupe aromatique monocyclique à 5 éléments éventuellement substitué contenant un hétéroatome sélectionné parmi O, S et N et contenant éventuellement un, deux ou trois atomes d'azote en plus de l'hétéroatome, (d) un cycloalkyle C3-7 éventuellement substitué et (e) un hétérocycle fusionné à benzo éventuellement substitué; R1 représente hydrogène, alkyle C1-4 ou halo; R2 et R3 représentent, indépendamment, hydrogène, OH, alcoxy C1-4, alkyle C1-4 ou alkyle C1-4 substitué par halo, OH, alcoxy C1-4 ou CN; X est indépendamment sélectionné parmi H, halo, alkyle C1-4, alkyle C1-4 halo-substitué, OH, alcoxy C1-4, alcoxy C1-4 halo-substitué, alkylthio C1-4, NO2, NH2, di-(C1-4alkyl)amino et CN; et n vaut 0, 1, 2, 3 et 4. Cette invention porte également sur une composition pharmaceutique utilisée dans le traitement d'un état pathologique dans lequel les prostaglandines sont impliquées comme agents pathogènes.

  该发明提供了式（I）的化合物或其药学上可接受的盐，其中Z代表OH，C1-6烷氧基，-NR2R3或杂环；Q从以下选取：（a）可选取取代苯基，（b）可选取含有一个、两个、三个或四个氮原子的6元单环芳香基，（c）可选取含有O、S和N中选取的一个杂原子的可选取取代的5元单环芳香基，并且除了所述杂原子外，还可含有一个、两个或三个氮原子，（d）可选取可选取取代的C3-7环烷基和（e）可选取取代的苯并杂环；R1代表氢、C1-4烷基或卤素；R2和R3独立地代表氢、OH、C1-4烷氧基、C1-4烷基或C1-4烷基取代的卤素、OH、C1-4烷氧基或CN；X独立地从H、卤素、C1-4烷基、卤素取代的C1-4烷基、OH、C1-4烷氧基、卤素取代的C1-4烷氧基、C1-4烷基硫、NO2、NH2、双（C1-4烷基）氨基和CN中选取；n为0、1、2、3和4。该发明还提供了一种药物组合物，用于治疗前列腺素作为病原体所涉及的医疗状况。
• 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS
  申请人：PFIZER INC.

  公开号：EP1045833A1

  公开（公告）日：2000-10-25
• US6608070B1
  申请人：——

  公开号：US6608070B1

  公开（公告）日：2003-08-19
• How Substrate Solvation Contributes to the Enantioselectivity of Subtilisin toward Secondary Alcohols
  作者：Christopher K. Savile、Romas J. Kazlauskas

  DOI：10.1021/ja0528937

  日期：2005.9.1

  The current rule to predict the enantiopreference of subtilisin toward secondary alcohols is based on the size of the substituents at the stereocenter and implies that the active site contains two differently sized pockets for these substituents. Several experiments are inconsistent with the current rule. First, the X-ray structures of subtilisin show there is only one pocket (the S1' pocket) approximately the size of a phenyl group to bind secondary alcohols. Second, the rule often predicts the incorrect enantiomer for reactions in water. To resolve these contradictions, we refine the current rule to show that subtilisin binds only one substituent of a secondary alcohol and leaves the other in solvent. To test this refined empirical rule, we show that the enantioselectivity of a series of secondary alcohols in water varied linearly with the difference in hydrophobicity (log P/P0) of the substituents. This hydrophobicity difference accounts for the solvation of one substituent in water.